Brainstorm Cell Therapeutics (BCLI) Stock Rating Reaffirmed by Maxim Group
Brainstorm Cell Therapeutics (NASDAQ:BCLI)‘s stock had its “buy” rating restated by stock analysts at Maxim Group in a research note issued on Thursday. They presently have a $9.00 price objective on the biotechnology company’s stock. Maxim Group’s target price indicates a potential upside of 128.43% from the company’s previous close.
The analysts wrote, “BrainStorm announced that the Office (USPTO) granted a new US patent titled Methods of Neurotrophic Factors”. The allowed claims for the patent cover the method for generating NurOwn (MSC-NTF cells) in industrial amounts for clinical practice.””
BCLI has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Brainstorm Cell Therapeutics in a research note on Tuesday, June 26th. ValuEngine upgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 16th.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its earnings results on Monday, July 23rd. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02). analysts predict that Brainstorm Cell Therapeutics will post -0.49 earnings per share for the current year.
A hedge fund recently raised its stake in Brainstorm Cell Therapeutics stock. Deutsche Bank AG boosted its position in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 330.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 98,590 shares of the biotechnology company’s stock after purchasing an additional 75,664 shares during the period. Deutsche Bank AG owned about 0.52% of Brainstorm Cell Therapeutics worth $386,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 11.78% of the company’s stock.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Read More: Hedge Funds – Risk or Reward?
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.